Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Investing.com - Avita Medical (NASDAQ: RCEL) reported third quarter EPS of $-0.62, $0.19 worse than the analyst estimate of $-0.43. Revenue for the quarter came in at $19.55M versus the consensus estimate of $19.44M.
Guidance
Avita Medical sees Q4 2024 revenue of $22.30M-$24.30M versus the analyst consensus of $23.52M.
Avita Medical's stock price closed at $12.40. It is up 29.57% in the last 3 months and up 19.92% in the last 12 months.
Avita Medical saw 1 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See Avita Medical's stock price’s past reactions to earnings here.
According to InvestingPro, Avita Medical's Financial Health score is "fair performance".
Check out Avita Medical's recent earnings performance, and Avita Medical's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar